Navigation Links
Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution
Date:4/20/2015

PASADENA, Calif., April 20, 2015 /PRNewswire-USNewswire/ -- Huntington Memorial Hospital is the first facility in the San Gabriel Valley to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure.

The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. The new system allows patients to transmit daily sensor readings from their homes to their health care providers allowing for personalized and proactive management to reduce the likelihood of hospitalization.

"CardioMEMS is an exciting and valuable tool and we are proud to bring this specialized care to our patients and the community," said Dr. Vyshali S. Rao, interventional cardiologist, who performs the procedure. "This innovative technology helps our physicians to treat and offers improved outcomes for heart failure patients."

Heart failure occurs when the heart is unable to pump enough blood to meet the body's demands. According to the Centers for Disease Control and Prevention, more than 5.1 million Americans have heart failure, with 670,000 new cases diagnosed each year. Patients with heart failure are frequently hospitalized, have a reduced quality of life and face a higher risk of death.

The CardioMEMS sensor is designed to last the lifetime of the patient and doesn't require batteries. Once implanted, the wireless sensor sends pressure readings to an external patient electronic system. There is no pain or sensation for the patient during the readings. The CardioMEMS HF System allows the patients to transmit critical information about their heart failure status to a clinician on a regular basis, without the need for additional clinic or hospital visits. This provides clinicians with the ability to detect worsening heart failure sooner and adjust treatment to reduce the likelihood that the patient will need to be hospitalized.

Data from a clinical trial showed that the CardioMEMS technology reduces heart failure hospital admissions by up to 37 percent. The CHAMPION trial studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System class III heart failure patients who had been hospitalized for heart failure in the previous 12 months. Results of the trial demonstrated a statistically significant 28 percent reduction in the rate of heart failure hospitalizations at six months, and 37 percent reduction in heart failure hospitalizations during an average follow-up duration of 15 months.

Roughly 1.4 million patients in the U.S. have NYHA Class III heart failure, and historically these patients account for nearly half of all heart failure hospitalizations. According to the American Heart Association, the estimated direct and indirect cost of heart failure in the U.S. for 2012 was $31 billion and that number is expected to more than double by 2030.

The CardioMEMS HF System, from global medical device manufacturer St. Jude Medical, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. For more information, visit http://www.heartfailureanswers.com/

About Huntington Hospital
Huntington Hospital, www.HuntingtonHospital.com, is a 625-bed not-for-profit hospital located in Pasadena, California. It has been ranked nationally by U.S. News and World Report in two specialties and was named among the top hospitals in California. The hospital is on Facebook at www.Facebook.com/HuntingtonMemorialHospital and on Twitter at @HuntingtonNews.

 


'/>"/>
SOURCE Huntington Memorial Hospital
Copyright©2015 PR Newswire.
All rights reserved

Related biology news :

1. Disease in a dish approach could aid Huntingtons disease discovery
2. Healthy tissue grafted to the brains of Huntingtons patients also develops the disease
3. Novel RNAi therapy silences mutated Huntingtons disease gene and reduces symptoms
4. Genetic diagnosis can rule out a suspected Huntingtons chorea patient
5. A new approach to Huntingtons disease?
6. Staying ahead of Huntingtons disease
7. Large animal models of Huntingtons disease offer new and promising research options
8. NCSU entomologist Fred Gould to present 2014 Founders Memorial Lecture
9. Memorial Sloan-Kettering researchers develop new method for tracking cell signaling
10. ACC Mascots Visit Patients at Brenner Childrens Hospital
11. Sharks skin has teeth in the fight against hospital superbugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2018)... MELBOURNE, Fla. (PRWEB) , ... August 15, 2018 , ... ... will be the NEW FX 635 Laser’s unveiling. Doctors from around the U.S. ... With the NEW FX 635, Erchonia Corporation completed another successful clinical trial ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... for the global scientific community, announced today the establishment of a new Scientific ... is to foster and support scientific collaborations with ActiGraph’s academic and pharmaceutical industry ...
(Date:8/9/2018)... ... August 09, 2018 , ... CRB is proud to ... has won Engineering News-Record (ENR) Texas & Louisiana’s 2018 Best Projects in the ... competition. The judges selected 42 projects across 18 categories as the region’s best. ...
Breaking Biology News(10 mins):
(Date:7/27/2018)... ... July 27, 2018 , ... ... Products Advocacy Group (BRAG®) and representatives of the Biotechnology Innovation Organization (BIO) ... groups’ recently-issued white paper, “Proposal for a Toxic Substances Control Act (TSCA) ...
(Date:7/25/2018)... ... 25, 2018 , ... Dimitrius Anagnos, an evidence-based healer, today ... and autoimmune disorders. , The preclinical research assessed biomarkers for systemic and ... Over 70% decrease in Interleukin (IL-1ß) expression , ...
(Date:7/25/2018)... ... July 25, 2018 , ... ... managing clinical trial patient and supplies data through its flagship IXRS® 3 ... IRT: Best Practices.” , This podcast features both Almac thought leaders and outside ...
(Date:7/24/2018)... ... 2018 , ... R3 Stem Cell is now offering regenerative therapies for COPD ... Double Board Certified providers, with outcomes significantly improving patient quality of life. , Traditional ... nothing to help repair and regenerate damaged lung tissues. Stem cell therapy for ...
Breaking Biology Technology: